Related Experiment Video
Updated: Feb 17, 2026
A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma DIPG
Published on: March 7, 2017
Developing chemotherapy for diffuse pontine intrinsic gliomas (DIPG)
Ho-Shin Gwak1, Hyeon Jin Park1
1Department of System Cancer Science, National Cancer Center Graduate School of Cancer Science and Policy, Goyang, Republic of Korea; Center for Pediatric Cancer, National Cancer Center, Goyang, Republic of Korea.
Abstract:
Prognosis of diffuse intrinsic pontine glioma (DIPG) is poor, with a median survival of 10 months after radiation. At present, chemotherapy has failed to show benefits over radiation. Advances in biotechnology have enabled the use of autopsy specimens for genomic analyses and molecular profiling of DIPG, which are quite different from those of supratentorial high grade glioma. Recently, combined treatments of cytotoxic agents with target inhibitors, based on biopsied tissue, are being examined in on-going trials. Spontaneous DIPG mice models have been recently developed that is useful for preclinical studies. Finally, the convection-enhanced delivery could be used to infuse drugs directly into the brainstem parenchyma, to which conventional systemic administration fails to achieve effective concentration. The WHO glioma classification defines a diffuse midline glioma with a H3-K27M-mutation, and we expect increase of tissue confirmation of DIPG, which will give us the biological information helping the development of a targeted therapy.
Insights
Diffuse intrinsic pontine glioma (DIPG) has a poor prognosis, with limited treatment options. New genomic insights and targeted therapies show promise for improving outcomes in this challenging pediatric brain tumor.
Area of Science:
- Pediatric neuro-oncology
- Molecular pathology of brain tumors
- Genomic analysis of gliomas
Background:
- Diffuse intrinsic pontine glioma (DIPG) presents a dismal prognosis, with median survival around 10 months post-radiation.
- Current chemotherapy offers limited benefits beyond radiation therapy for DIPG.
- DIPG molecular profiles differ significantly from supratentorial high-grade gliomas.
Purpose of the Study:
- To review advances in understanding DIPG biology and treatment strategies.
- To highlight the potential of new therapeutic approaches for DIPG.
- To discuss the implications of the WHO classification on DIPG research.
Main Methods:
- Genomic analyses and molecular profiling of autopsy specimens.
- Examination of combined cytotoxic and targeted inhibitor treatments in ongoing trials.
- Utilizing spontaneous DIPG mouse models for preclinical studies.
- Investigating convection-enhanced delivery for direct brainstem drug infusion.
Main Results:
- Biotechnology advances allow for detailed genomic and molecular characterization of DIPG.
- New DIPG mouse models facilitate preclinical therapeutic evaluations.
- Convection-enhanced delivery offers a potential route for localized drug delivery to the brainstem.
- The WHO classification identifies diffuse midline gliomas with H3-K27M-mutation, aiding DIPG identification.
Conclusions:
- Genomic insights into DIPG are crucial for developing targeted therapies.
- Combined treatment strategies and novel drug delivery methods show therapeutic potential.
- Accurate tissue confirmation and molecular profiling are key to advancing DIPG treatment and improving patient survival.
